In this article, we will be taking a look at the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now.
Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks. Finding quality opportunities is still difficult in an unpredictable macroeconomic climate, even if many low-cost stocks operate in high-growth industries that profit from long-term structural trends.
The Middle East war has been one of 2026’s defining issues. In its June 15 article, “Iran deal could expand market gains, with consumer shares, small caps seen benefiting,” Reuters stated that lower oil prices and easing geopolitical tensions could boost consumer spending, lower Treasury yields and inflationary pressures, and strengthen economically sensitive sectors like consumer stocks, small caps, and energy-dependent markets. Strategists at JPMorgan observed,
“If our positive macro view plays out – underpinned by strong earnings, stable inflation expectations, and an easing of geopolitical risks in the second half – cyclicals should remain well positioned to outperform through year-end.”
However, uncertainty resurfaced on June 20 when Reuters reported that Iran had closed the Strait of Hormuz following suspected ceasefire violations.
Many market experts are still positive about stocks in spite of these occurrences. While maintaining a preference for U.S. large-cap growth stocks driven by attractive valuations and AI-powered earnings, T. Rowe Price’s Sébastien Page stated in an interview with CNBC on May 13 that record market highs are not trustworthy sell signals, pointing out that expected S&P 500 earnings growth increased from 13% at the end of March to 27%. Chris Veronne of Strategas observed weakness in consumer stocks and banks on May 12, but pointed out that there was little rotation into defensive sectors, indicating that investors had not generally become risk-averse.
In a similar vein, Callanish Capital CEO Haig Bathgate told CNBC on May 7 that long-term performance is influenced by things like artificial intelligence (AI), capital expenditure cycles, and global energy trends, and that geopolitical conflicts usually cause short-term volatility rather than long-term market harm. Scott Chronert of Citi stated on CNBC’s Closing Bell on March 24 that while sentiment has improved due to the lessening of tensions, liquidity, interest rates, oil prices, currency volatility, earnings, and broader macroeconomic fundamentals would ultimately determine the market’s longer-term trajectory.
Together, these perspectives imply that long-term stock performance is still influenced by earnings growth, policy, innovation, and economic fundamentals, even though geopolitical events can momentarily affect sentiment and market timing.
With that said, let’s take a look at the best up and coming stocks.
Our Methodology
For our methodology, we identified pharmaceutical companies that went public within the last five years. From this list, we selected companies with the most recent news and significant developments. We then ranked these companies based on their total number of hedge fund holders as of Q1 2026, according to the Insider Monkey database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Here is our list of the 8 best up-and-coming pharmaceutical stocks to buy now.
8. Eikon Therapeutics, Inc. (NASDAQ:EIKN)
Number of Hedge Fund Holders: 12
Eikon Therapeutics, Inc. (NASDAQ:EIKN) is one of the best up and coming stocks on our list.
TheFly reported on June 3 that BofA Securities lowered its price target for EIKN to $32 from $34 while maintaining a Buy rating on the shares. The firm noted that the company’s first-quarter results showed steady advancement in its development initiatives, despite the report being relatively limited in major updates. The revised price target reflected an updated share count assessment.
Eikon Therapeutics, Inc. reached an important market milestone on June 25 as the company confirmed its upcoming inclusion in the Russell 3000 Index. The addition will take place following the annual reconstitution of the index and will become effective after the close of trading in the U.S. market on June 26, 2026. Being included in the Russell 3000 Index places EIKN among a broader group of publicly traded companies tracked by investors and institutions, potentially increasing visibility and market exposure. This development reflects the company’s continued growth and recognition within the broader U.S. equity market.
Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing breakthrough medicines by combining super-resolution microscopy, engineering, and machine learning to study protein dynamics and discover new drug targets for oncology and neurological diseases.
7. AgomAB Therapeutics NV (NASDAQ:AGMB)
Number of Hedge Fund Holders: 16
AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list.
TheFly reported on June 22 that H.C. Wainwright initiated coverage of AGMB with a Buy rating and assigned a $35 price target. The firm highlighted that AGMB’s two clinical programs are designed to deliver targeted drug activity within affected tissues while minimizing systemic exposure through rapid inactivation after absorption. The company’s approach aims to utilize the antifibrotic potential of ALK5 inhibition across conditions, including fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis, supporting the potential of its therapeutic pipeline.
Later, on June 23, AgomAB Therapeutics NV announced the planned Phase 2b NOV-ERA trial evaluating ontunisertib, an investigational oral ALK5 inhibitor designed for the potential treatment of fibrostenosing Crohn’s disease. The company confirmed alignment with the FDA on the trial framework, including the primary endpoint focused on endoscopic passability at Week 24 and additional secondary measures. The study protocol has been submitted, with regulatory progress also advancing through approvals in the U.S. and Canada. Agomab expects to begin the trial in the second half of 2026, with the global randomized study planned to evaluate the safety and effectiveness of ontunisertib in up to 320 adult patients.
AgomAB Therapeutics NV is a clinical-stage biotech company developing therapies for fibro-inflammatory and autoimmune diseases using small molecules and regenerative antibodies to reduce inflammation and restore organ function.
6. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP)
Number of Hedge Fund Holders: 16
CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) is one of the best up and coming stocks on our list.
TheFly reported on June 16 that JPMorgan upgraded CAMP4 to Overweight from Neutral and increased its price target to $9 from $5. The firm noted that the company’s shares appear undervalued due to the potential of CMP-002 in treating SYNGAP1-related disorder. JPMorgan also highlighted that CAMP’s upcoming September research and development event could provide further insight into the company’s future pipeline opportunities. Additionally, the firm pointed out that CAMP has completed GLP toxicology studies for CMP-002 and has received regulatory guidance from multiple jurisdictions, supporting continued advancement of the program.
Earlier on May 14, CAMP4 THERAPEUTICS CORPORATION announced new preclinical findings for CMP-002, its investigational antisense oligonucleotide candidate for SYNGAP1-related disorder, at the TIDES Oligonucleotide & Peptide Therapeutics conference. The company reported that CMP-002 treatment resulted in statistically significant improvements in seizure resistance and reduced seizure severity in SYNGAP1 haploinsufficient mice. The data further supported the potential of CMP-002 to restore SYNGAP1 protein levels and address key disease characteristics associated with the disorder. CAMP stated that these findings strengthen the program’s development path and that the company plans to move CMP-002 into a Phase 1/2 clinical trial in the second half of 2026.
CAMP4 THERAPEUTICS CORPORATION is a clinical-stage biotech company developing RNA-based therapies using its proprietary platform to increase gene expression and treat genetic diseases affecting the nervous system and liver.
5. LB Pharmaceuticals Inc. (NASDAQ:LBRX)
Number of Hedge Fund Holders: 24
LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list.
TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that Neumora Therapeutics’ Phase 3 KOASTAL trial setback does not materially impact the outlook for LB-102. Clear Street highlighted that LB-102 is supported by established dopamine D2/D3 and serotonin 5-HT7 receptor activity, along with prior clinical evidence from related therapies. The firm also noted that LB-102 has shown strong Phase 2 results in schizophrenia and believes the company’s broader opportunities across schizophrenia, bipolar disorder, and major depressive disorder remain unchanged.
In addition to that, earlier on May 12, in its latest reported earnings for fiscal Q1 2026, LB Pharmaceuticals Inc. provided a corporate update and reported financial results for the quarter ended March 31, 2026. Research and development expenses increased to $14.6 million, driven by higher clinical trial activity, manufacturing costs for LB-102, preclinical programs, and expanded personnel expenses. General and administrative expenses rose to $7.5 million due to increased staffing, stock-based compensation, and professional fees. The company reported a net loss of $19.1 million for the quarter. LB Pharmaceuticals ended the period with approximately $365.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2029.
LB Pharmaceuticals Inc. is a late-stage biotech company developing neuropsychiatric therapies, including LB-102, a novel treatment candidate for schizophrenia, bipolar depression, and major depressive disorder.
4. Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
Number of Hedge Fund Holders: 26
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is one of the best up and coming stocks on our list.
TheFly reported on June 25 that JPMorgan adjusted its price target for LXEO, lowering it to $9 from $12 while maintaining an Overweight rating on the shares. The firm stated that the revision was based on an updated valuation model incorporating the company’s latest developments and recent updates.
Separately, on June 15, Lexeo Therapeutics, Inc. announced the completion of the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006, its gene therapy candidate targeting Friedreich’s ataxia cardiomyopathy. The finalized study design is intended to support a potential FDA biologics license application submission under the accelerated approval pathway in 2028. The FDA confirmed that no additional nonclinical bridging studies are required, allowing LXEO to proceed with patient dosing using its optimized manufacturing process. The company expects SUNRISE-FA 2 topline data in the second half of 2027, followed by a potential BLA submission in the first half of 2028.
Lexeo Therapeutics, Inc. is a clinical-stage biotech company developing AAV-based gene therapies for genetic cardiovascular diseases and APOE4-associated Alzheimer’s disease.
3. Alto Neuroscience, Inc. (NYSE:ANRO)
Number of Hedge Fund Holders: 30
Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list.
On June 15, ALTO highlighted the publication in Nature Medicine of Prime-Praxol, an independent randomized, double-blind, placebo-controlled study evaluating pramipexole, a dopamine agonist, in patients with mood disorders and clinically significant anhedonia. The trial, independently conducted and funded by investigators at Lund University in Sweden, included adults with major depressive disorder, dysthymia, or bipolar depression. Participants received flexible-dose pramipexole or placebo alongside existing treatment for nine weeks, followed by a six-month open-label extension. The study showed that pramipexole produced a greater reduction in anhedonia compared with placebo, with improvements sustained during the extension period.
In another company news, it was reported on May 28 that Alto Neuroscience, Inc. announced the appointment of Andrew Miller, Ph.D., to its Board of Directors, effective May 27, 2026. The company highlighted Dr. Miller’s extensive experience in neuropsychiatric drug development, strategic leadership, and advancing novel therapies for serious mental health conditions. Miller previously served as Founder and President of R&D at Karuna Therapeutics, where he played a key role in developing KarXT, a schizophrenia treatment later acquired by Bristol Myers Squibb. ALTO noted that its expertise will support the company as it advances ALTO-207 in treatment-resistant depression and progresses its broader precision psychiatry pipeline toward future clinical milestones.
Alto Neuroscience, Inc. is a clinical-stage biotech company developing personalized treatments for neuropsychiatric disorders using its AI-driven Precision Psychiatry Platform.
2. Septerna, Inc. (NASDAQ:SEPN)
Number of Hedge Fund Holders: 31
Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list.
TheFly reported on June 11 that Guggenheim began coverage of SEPN with a Buy rating and assigned the company a $52 price target.
In another operational update, Septerna, Inc. highlighted progress with SEP-479, announcing on June 8 that the first comprehensive preclinical characterization of the candidate had been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026). The presentation will focus on the pharmacological profile of SEP-479, a selective small-molecule PTH1R agonist being developed as a potential oral treatment for hypoparathyroidism. SEPN reported that preclinical studies demonstrated strong activity in both laboratory and animal models, supporting the candidate’s potential as an oral therapy.
SEP-479 is currently being evaluated in a Phase 1 trial involving healthy volunteers, with initial data expected in late 2026 or early 2027. The company stated that these findings further demonstrate the potential of its Native Complex Platform to develop oral small molecules targeting challenging GPCR pathways. SEPN believes SEP-479 could provide a once-daily oral approach designed to replace PTH activity and potentially improve treatment options for patients with hypoparathyroidism.
Septerna, Inc. is a clinical-stage biotech company developing oral small-molecule drugs targeting GPCRs to treat endocrine, immune, inflammatory, and metabolic diseases.
1. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Number of Hedge Fund Holders: 53
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best up and coming stocks on our list.
TheFly reported on June 14 that MLYS presented new data evaluating the impact of lorundrostat on heart failure risk biomarkers. The post hoc analysis examined circulating protein biomarker data from participants in the Launch-HTN and Advance-HTN clinical trials and was presented during a late-breaking poster session at ENDO 2026. The analysis showed that lorundrostat influenced key components of the renin-angiotensin-aldosterone system, including increased renin levels and reduced angiotensinogen. Treatment was also associated with declines in several biomarkers linked to heart failure risk, including NT-proBNP. The findings supported further investigation of lorundrostat’s potential role in addressing biological pathways involved in heart failure.
Moreover, to support its future growth initiatives and strengthen its financial position, Mineralys Therapeutics, Inc. announced the pricing of an underwritten public offering of 5.66 million shares of common stock at $26.50 per share on June 3. The offering is expected to generate approximately $150 million in gross proceeds before fees and expenses. MLYS plans to use the net proceeds to help fund a portion of the $200 million upfront payment related to the repurchase of its royalty obligation under its license agreement with Tanabe Pharma Corporation. The offering followed the company’s announcement of a $500 million committed debt facility managed by Pharmakon Advisors.
Mineralys Therapeutics, Inc. is a clinical-stage biotech company developing therapies for aldosterone-driven diseases, including resistant hypertension and chronic kidney disease.
READ NEXT: 10 UK Stocks with the Highest Dividends and 10 Best Falling Stocks to Invest In According to Analysts.
Hedge Fund Resource Center